Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Targets of Neuroprotection in Glaucoma.

He S, Stankowska DL, Ellis DZ, Krishnamoorthy RR, Yorio T.

J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):85-106. doi: 10.1089/jop.2017.0041. Epub 2017 Aug 18. Review.

2.

Translational Pharmacology in Glaucoma Neuroprotection.

Levin LA.

Handb Exp Pharmacol. 2017;242:209-230. doi: 10.1007/164_2016_20.

PMID:
27752844
4.

Disease progression and the need for neuroprotection in glaucoma management.

Varma R, Peeples P, Walt JG, Bramley TJ.

Am J Manag Care. 2008 Feb;14(1 Suppl):S15-9. Review.

5.

Management of glaucoma as a neurodegenerative disease.

Jutley G, Luk SM, Dehabadi MH, Cordeiro MF.

Neurodegener Dis Manag. 2017 Apr;7(2):157-172. doi: 10.2217/nmt-2017-0004. Epub 2017 May 22. Review.

PMID:
28540772
6.

Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.

Chen YS, Green CR, Danesh-Meyer HV, Rupenthal ID.

Eur J Pharm Biopharm. 2015 Sep;95(Pt B):182-93. doi: 10.1016/j.ejpb.2015.01.031. Epub 2015 Feb 9. Review.

PMID:
25676338
7.

Neuroprotective Strategies in Glaucoma.

Gossman CA, Christie J, Webster MK, Linn DM, Linn CL.

Curr Pharm Des. 2016;22(14):2178-92. Review.

PMID:
26818878
8.

Neuroprotection in glaucoma: drug-based approaches.

Cheung W, Guo L, Cordeiro MF.

Optom Vis Sci. 2008 Jun;85(6):406-16. doi: 10.1097/OPX.0b013e31817841e5. Review.

9.

Neuroprotection in Glaucoma: Animal Models and Clinical Trials.

Almasieh M, Levin LA.

Annu Rev Vis Sci. 2017 Sep 15;3:91-120. doi: 10.1146/annurev-vision-102016-061422. Epub 2017 Jul 21. Review.

PMID:
28731838
10.

Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.

Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA.

Prog Brain Res. 2008;173:451-64. doi: 10.1016/S0079-6123(08)01131-X. Review.

PMID:
18929127
11.

Neuroprotection for treatment of glaucoma in adults.

Sena DF, Lindsley K.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006539. doi: 10.1002/14651858.CD006539.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jan 25;1:CD006539.

12.

[Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma].

Mao WM, Liu Y, Wordinger YH, Clark AF, Pang IH.

Zhonghua Yan Ke Za Zhi. 2016 Jun 11;52(6):471-5. doi: 10.3760/cma.j.issn.0412-4081.2016.06.019. Review. Chinese.

PMID:
27373575
13.

Upregulation of the endothelin A (ETA) receptor and its association with neurodegeneration in a rodent model of glaucoma.

McGrady NR, Minton AZ, Stankowska DL, He S, Jefferies HB, Krishnamoorthy RR.

BMC Neurosci. 2017 Mar 1;18(1):27. doi: 10.1186/s12868-017-0346-3.

14.

Is neuroprotection a viable therapy for glaucoma?

Weinreb RN, Levin LA.

Arch Ophthalmol. 1999 Nov;117(11):1540-4. Review.

PMID:
10565524
15.

Neuroprotection for treatment of glaucoma in adults.

Sena DF, Lindsley K.

Cochrane Database Syst Rev. 2017 Jan 25;1:CD006539. doi: 10.1002/14651858.CD006539.pub4. Review.

16.

Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.

Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, Oddone F.

Int J Mol Sci. 2015 Nov 30;16(12):28401-17. doi: 10.3390/ijms161226099. Review.

17.

Protecting the retinal neurons from glaucoma: lowering ocular pressure is not enough.

Pascale A, Drago F, Govoni S.

Pharmacol Res. 2012 Jul;66(1):19-32. doi: 10.1016/j.phrs.2012.03.002. Epub 2012 Mar 14. Review.

PMID:
22433276
18.

Current and emerging medical therapies in the treatment of glaucoma.

Bagnis A, Papadia M, Scotto R, Traverso CE.

Expert Opin Emerg Drugs. 2011 Jun;16(2):293-307. doi: 10.1517/14728214.2011.563733. Epub 2011 Apr 7. Review.

PMID:
21406029
19.

Primary open-angle glaucoma.

Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR.

Nat Rev Dis Primers. 2016 Sep 22;2:16067. doi: 10.1038/nrdp.2016.67. Review.

PMID:
27654570
20.

Leptin as a neuroprotective agent in glaucoma.

Gupta A.

Med Hypotheses. 2013 Nov;81(5):797-802. doi: 10.1016/j.mehy.2013.08.023. Epub 2013 Aug 29.

PMID:
24035688

Supplemental Content

Support Center